Background illustration for clinical trials search

Multiple Myeloma Clinical Trials

Browse 1,243 multiple myeloma clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
Featured

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma
Location: New York NY, Newark DE, Fairfax VA, Chapel Hill NC,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT05650632

Phase1, Recruiting
Featured

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

for
Multiple Myeloma
Location: New Haven CT, Washington D.C. DC, Winston-Salem NC,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT07555938

Phase3, Recruiting
Featured

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

for
Multiple Myeloma
Location: Boston MA, New Haven CT, New York NY, Chapel Hill NC,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06953960

Phase1, Phase2, Recruiting
Active & Responsive

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

for
Relapsed/Refractory Multiple Myeloma
Location: New York NY, Hackensack NJ, Richmond VA, Durham NC,
Sponsor: Caribou Biosciences, Inc.

Sex: All

Age: 18+

Code: NCT05722418

Phase1, Recruiting
Active & Responsive

64Cu-LLP2A for Imaging Hematologic Malignancies

for
Multiple Myeloma, Low-Grade Lymphoma, Follicular Lymphoma,
Location: St Louis MO
Sponsor: Washington University School of Medicine

Sex: All

Age: 18+

Code: NCT06636175

Early_phase1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & ResponsiveNew

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

for
Relapsed or Refractory Multiple Myeloma
Location: Duarte CA
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT07681596

Phase1, Phase2, Recruiting
Active & ResponsiveNew

Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

for
Multiple Myeloma
Location: La Crosse WI
Sponsor: PrECOG, LLC.

Sex: All

Age: 18 - 70+

Code: NCT07285239

Phase3, Recruiting
Active & Responsive

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

for
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Location: Omaha NE, West Hollywood CA
Sponsor: Oncotherapeutics

Sex: All

Age: 0+

Code: NCT06115135

Phase2, Recruiting
Active & Responsive

Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

for
Multiple Myeloma
Location: St. John's, Halifax, Montreal, Toronto, London,
Sponsor: Canadian Myeloma Research Group

Sex: All

Age: 65+

Code: NCT05272826

Phase2, Recruiting
Active & Responsive

Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma

for
Multiple Myeloma (MM)
Location: Maywood IL, Milwaukee WI
Sponsor: Medical College of Wisconsin

Sex: All

Age: 18+

Code: NCT07236502

Recruiting
Active & Responsive

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

for
Relapsed Refractory Multiple Myeloma
Location: New Haven CT, New York NY, Montreal, Winston-Salem NC,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT07391657

Phase3, Recruiting
Active & Responsive

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

for
Multiple Myeloma in Relapse, Myeloma Multiple,
Location: Boston MA, Hackensack NJ, Tampa FL, Atlanta GA,
Sponsor: Kelonia Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07075185

Phase1, Recruiting
Active & Responsive

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

for
Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Location: New York NY, Chapel Hill NC, Jacksonville FL,
Sponsor: C4 Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07284758

Phase2, Recruiting
Active & Responsive

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

for
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Location: Durham NC
Sponsor: Duke University

Sex: All

Age: 18+

Code: NCT06822972

Phase2, Recruiting
Active & Responsive

Radiofrequency Ablation for BIII Thyroid Nodules

for
Indeterminate Bethesda III Thyroid Nodules
Location: New York NY
Sponsor: Columbia University

Sex: All

Age: 18+

Code: NCT05189808

Recruiting
Active & Responsive

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

for
Clinical Stage III Cutaneous Melanoma AJCC v8,
Location: Springfield MA, Mineola NY, New York NY,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05136196

Phase2, Recruiting
Active & Responsive

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

for
Plasma Cell Myeloma
Location: Exeter NH, Westerly RI, Waterford CT, Guilford CT,
Sponsor: SWOG Cancer Research Network

Sex: All

Age: 0+

Code: NCT05561387

Phase3, Recruiting
Active & ResponsiveNew

A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

for
Lupus Nephritis, Systemic Lupus Erythematosus,
Location: Fayetteville NC, Miami FL, Cooper City FL,
Sponsor: Fate Therapeutics

Sex: All

Age: 12 - 70

Code: NCT07570862

Phase2, Recruiting
Active & Responsive

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

for
Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma,
Location: Atlanta GA
Sponsor: Emory University

Sex: All

Age: 18+

Code: NCT06495125

Phase2, Recruiting
Active & Responsive

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

for
Metastatic Colorectal Adenocarcinoma,
Location: Baltimore MD, Washington D.C. DC, Atlanta GA, Aurora CO
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07147231

Phase1, Phase2, Recruiting